Mediwound Ltd (NASDAQ:MDWD) — Market Cap & Net Worth
Market Cap & Net Worth: Mediwound Ltd (MDWD)
Mediwound Ltd (NASDAQ:MDWD) has a market capitalization of $213.45 Million ($213.45 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16288 globally and #3679 in its home market, demonstrating a -0.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mediwound Ltd's stock price $16.63 by its total outstanding shares 12835186 (12.84 Million). Analyse MDWD operating cash flow to see how efficiently the company converts income to cash.
Mediwound Ltd Market Cap History: 2015 to 2026
Mediwound Ltd's market capitalization history from 2015 to 2026. Data shows change from $767.29 Million to $213.45 Million (-10.62% CAGR).
Index Memberships
Mediwound Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #442 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1586 of 3165 |
Weight: Mediwound Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mediwound Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mediwound Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.30x
Mediwound Ltd's market cap is 11.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $767.29 Million | $601.00K | -$22.09 Million | 1276.68x | N/A |
| 2016 | $411.42 Million | $1.56 Million | -$18.89 Million | 264.07x | N/A |
| 2017 | $399.82 Million | $2.50 Million | -$22.15 Million | 160.18x | N/A |
| 2018 | $364.78 Million | $3.40 Million | -$1.06 Million | 107.26x | N/A |
| 2019 | $278.52 Million | $31.79 Million | $4.96 Million | 8.76x | 56.21x |
| 2020 | $332.43 Million | $21.76 Million | -$9.20 Million | 15.28x | N/A |
| 2021 | $212.04 Million | $23.76 Million | -$13.55 Million | 8.92x | N/A |
| 2022 | $173.15 Million | $26.50 Million | -$19.60 Million | 6.53x | N/A |
| 2023 | $130.53 Million | $18.69 Million | -$6.72 Million | 6.99x | N/A |
| 2024 | $228.47 Million | $20.22 Million | -$30.22 Million | 11.30x | N/A |
Competitor Companies of MDWD by Market Capitalization
Companies near Mediwound Ltd in the global market cap rankings as of May 5, 2026.
Key companies related to Mediwound Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Mediwound Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Mediwound Ltd's market cap moved from $767.29 Million to $ 213.45 Million, with a yearly change of -10.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $213.45 Million | -9.91% |
| 2025 | $236.94 Million | +3.71% |
| 2024 | $228.47 Million | +75.02% |
| 2023 | $130.53 Million | -24.61% |
| 2022 | $173.15 Million | -18.34% |
| 2021 | $212.04 Million | -36.22% |
| 2020 | $332.43 Million | +19.35% |
| 2019 | $278.52 Million | -23.65% |
| 2018 | $364.78 Million | -8.76% |
| 2017 | $399.82 Million | -2.82% |
| 2016 | $411.42 Million | -46.38% |
| 2015 | $767.29 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Mediwound Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $213.45 Million USD |
| MoneyControl | $213.45 Million USD |
| MarketWatch | $213.45 Million USD |
| marketcap.company | $213.45 Million USD |
| Reuters | $213.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more